Huons Group has been selected for a national project aimed at stabilizing the supply of orphan and essential drugs, strengthening access to treatment for patients with rare and intractable diseases in Korea.

Huons Co., Ltd. (CEO Soo-young Song) announced on September 22 that it has been chosen as the development institution for Phase 2, Round 3 of the Stable Supply of National Essential Drugs project, supervised by the Korea Orphan & Essential Drug Center (KOEDC). The government initiative supports the development of technologies that ensure reliable supply of medicines vital to patients but vulnerable to shortages.

The two items selected under this project are Sodium Acetate Injection and Flecainide Injection. Huons will receive approximately $122,000 in annual government funding per item to conduct one year of research.

Sodium Acetate Injection is an essential therapy for preventing and correcting hyponatremia, diagnosing Brugada syndrome, and treating severe cardiac arrhythmias in emergencies. Both drugs are currently reliant on imports due to their small market size and limited prescription volume. As a result, any supply disruption poses a significant risk, underscoring the need for domestic production and stable national management.

Through this project, Huons aims to secure South Korean manufacturing technology, localize production, and establish a resilient supply chain. This will provide a reliable foundation for delivering essential treatments to patients and reinforce the national healthcare safety net.

Building on its R&D expertise and advanced injectable drug manufacturing facilities, Huons plans to further strengthen its role as a leading supplier of orphan and essential medicines in Korea.

CEO Soo-young Song emphasized, “The stable supply of orphan and essential drugs is difficult if viewed solely from a market perspective. However, through public-private partnerships and an ESG approach, we can safeguard patient safety and treatment rights.” He added, “Huons will continue to secure high-quality production technologies for these critical drugs and contribute to public health while fulfilling our social responsibilities.”